Daryl Sudasena
Interventional Cardiology · Olympia, WANPI 1295153880
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.7%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Medtronic at 39.6% of the total.
Across 138 payments — averaging $80.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Boston Scientific$1K
- Philips North America LLC$1K
- Abbott$1K
- Stryker$956
- AstraZeneca$466
- plus $2K from 15 others
What the payments were for
- Grants$1,10510%
- Travel & lodging$4,83043%
- Food & beverage$5,08546%
- Education$1191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 35 | $4,409 |
| Boston Scientific | 7 | $1,320 |
| Philips North America LLC | 6 | $1,234 |
| Abbott | 13 | $1,035 |
| Stryker | 9 | $956 |
| AstraZeneca | 11 | $466 |
| Cardiovascular Systems Inc. | 18 | $326 |
| Amgen | 8 | $264 |
| Cvrx, Inc. | 1 | $211 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $180 |
| Abiomed | 3 | $161 |
| Chiesi USA, Inc. | 3 | $136 |
| Novartis | 1 | $118 |
| Boehringer Ingelheim | 3 | $70 |
| Novo Nordisk | 1 | $67 |
| Johnson & Johnson(2 entities) | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $42 |
| Lantheus Medical Imaging, Inc. | 3 | $39 |
| Astellas Pharma US Inc | 1 | $25 |
| Bayer | 1 | $20 |
| Pfizer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - STRUCTURAL$1,105
- (9520) IGT Devices Undivided$973
- Micra$644
- FlowTriever$424
- FLOWTRIEVER CATHETER, S$419
- CT THROMBECTOMY SYSTEM KIT$419
- ADVISA DR MRI SURESCAN$286
- MitraClip$265
- ATTESTA SR MRI SURESCAN$220
- Barostim Neo System$211
- CardioMEMS HF System$148
- Confirm Rx$145
- FARXIGA$118
- ENTRESTO$118
- Impella$117
- (6571) Eagle Eye$114
- Repatha$108
- KENGREAL$103
How this compares
$11,139 in reported general payments places this provider in the 70th percentile of 125 interventional cardiology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 278 | $363,258 |
| JardianceEmpagliflozin | 90 | $108,876 |
| FarxigaDapagliflozin Propanediol | 68 | $58,855 |
| XareltoRivaroxaban | 60 | $58,428 |
| EntrestoSacubitril/Valsartan | 42 | $44,672 |
| Repatha SureclickEvolocumab | 42 | $27,772 |
| WegovySemaglutide | 13 | $18,694 |
| BrilintaTicagrelor | 15 | $10,089 |
| Metoprolol Succinate | 641 | $8,155 |
| Digoxin | 50 | $5,529 |
| Amiodarone Hcl | 86 | $5,321 |
| Atorvastatin Calcium | 265 | $3,823 |
| Ranolazine ErRanolazine | 36 | $3,622 |
| Potassium Chloride | 139 | $2,798 |
| Rosuvastatin Calcium | 155 | $2,762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17 | $363,258278 claims |
| Boehringer IngelheimJardiance | $70 | $108,87690 claims |
| AstraZenecaFarxiga, Brilinta | $466 | $68,94483 claims |
| Johnson & JohnsonXarelto | $45 | $58,42860 claims |
| NovartisEntresto | $118 | $44,67242 claims |
| Novo NordiskWegovy | $67 | $18,69413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 125 interventional cardiology providers in Washington.
Other interventional cardiology in Olympia
- Gopal GhimireOlympia$35K
- John WaggonerOlympia$11K
- Rami KafaOlympia$6K
- William LombardiSeattle$902K
- Kathleen KearneySeattle$448K
- Robert RileyBellevue$431K
- Danny DvirSeattle$374K
- James McCabeSeattle$289K
- Christopher BrownSeattle$266K
- Lorenzo AzzaliniSeattle$233K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.